JPS63150210A - Hair-tonic cosmetic - Google Patents
Hair-tonic cosmeticInfo
- Publication number
- JPS63150210A JPS63150210A JP29816186A JP29816186A JPS63150210A JP S63150210 A JPS63150210 A JP S63150210A JP 29816186 A JP29816186 A JP 29816186A JP 29816186 A JP29816186 A JP 29816186A JP S63150210 A JPS63150210 A JP S63150210A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- molecular weight
- aminobutyric acid
- components selected
- hair growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 20
- 210000004209 hair Anatomy 0.000 claims abstract description 54
- 230000002378 acidificating effect Effects 0.000 claims abstract description 14
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 11
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 10
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 9
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 9
- 229920000045 Dermatan sulfate Polymers 0.000 claims abstract description 6
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims abstract description 6
- 229940051593 dermatan sulfate Drugs 0.000 claims abstract description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 6
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000011159 matrix material Substances 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 25
- 210000004761 scalp Anatomy 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 10
- 206010039792 Seborrhoea Diseases 0.000 abstract description 8
- 238000013329 compounding Methods 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000003779 hair growth Effects 0.000 description 38
- 238000012360 testing method Methods 0.000 description 20
- 229940124277 aminobutyric acid Drugs 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 235000015961 tonic Nutrition 0.000 description 7
- 230000001256 tonic effect Effects 0.000 description 7
- 208000001840 Dandruff Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- -1 octyl ester Chemical class 0.000 description 5
- 201000004384 Alopecia Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000003658 preventing hair loss Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical class [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 229960000716 tonics Drugs 0.000 description 3
- NPSJHQMIVNJLNN-UHFFFAOYSA-N 2-ethylhexyl 4-nitrobenzoate Chemical compound CCCCC(CC)COC(=O)C1=CC=C([N+]([O-])=O)C=C1 NPSJHQMIVNJLNN-UHFFFAOYSA-N 0.000 description 2
- 239000004808 2-ethylhexylester Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004215 skin function Effects 0.000 description 2
- AOKCDAVWJLOAHG-UHFFFAOYSA-N 4-(methylamino)butyric acid Chemical compound C[NH2+]CCCC([O-])=O AOKCDAVWJLOAHG-UHFFFAOYSA-N 0.000 description 1
- 108700016947 Bos taurus structural-GP Proteins 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 150000008535 L-arginines Chemical class 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000003450 growing effect Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
少なくとも一種と、Ｔ−アミノ醋酸及びその誘導体より
選ばれた少なくとも一種とを配合してなる養毛化粧料に
関する。更に詳しくは、頭髪に直接塗布して毛母細胞を
賦活し、育毛、養毛、脱毛予防、ふけ防止等の効果に優
れた養毛化粧料に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a hair nourishing cosmetic comprising at least one type and at least one selected from T-aminoacetic acid and its derivatives. More specifically, the present invention relates to a hair-growth cosmetic that is applied directly to hair to activate hair matrix cells and has excellent effects such as hair growth, hair growth, hair loss prevention, and dandruff prevention.
（従来技術）
従来より、毛母細胞賦活作用又は血行促進作用を有する
成分を配合してなる養毛化粧料が種々提案されてきたが
、これら提案された養毛化粧料いずれもが、積極的に育
毛効果又は養毛効果を期待する程度に優れた養毛料を得
ることは困難であった。(Prior art) Various hair nourishing cosmetics containing ingredients that have hair matrix activation or blood circulation promoting effects have been proposed, but all of these proposed hair nourishing cosmetics have It has been difficult to obtain a hair nourishing agent that is excellent enough to have a hair growing effect or a hair nourishing effect.
確かに、育毛、養毛、更には発毛効果までを期待するた
めには、毛母細胞賦活作用または血行促進作用を有する
成分を養毛料に配合することが、適当なる技術的条件で
あっても、それだけの技術的要素のみで、期待する程度
の発毛効果が発現するものではない。It is true that in order to expect hair growth, hair growth, and even hair growth effects, it is an appropriate technical condition to include ingredients that have hair matrix activation or blood circulation promoting effects in the hair nourishment. However, it is not possible to achieve the expected level of hair growth effect due to only those technical factors.
即ち、毛包上皮に存在する毛母細胞は、その周辺を真皮
で取り囲まれていて、頭皮内に存在する末梢毛細血管か
ら滲出してくる毛母細胞賦活成分や毛母細胞の栄養素は
、毛包上皮周辺に存在する真皮構成成分、特に、構造性
糖蛋白とともに、線雄性蛋白の間隙を埋めている頭皮の
基質成分である酸性ムコ多糖類、例えば、ヒアルロン酸
、デルマタン硫酸、コンドロイチン硫酸、ヘパラン硫酸
等の基質成分層を泳動して、毛母細胞に到達し、毛母細
胞内に取り込まれることによって、期待せる育毛、養毛
、更には発毛効果が発現するのである。In other words, the hair matrix cells present in the hair follicle epithelium are surrounded by the dermis, and the hair matrix cell activation components and hair matrix nutrients exuded from the peripheral capillaries in the scalp are absorbed by the hair matrix. Dermal constituents present around the foreskin epithelium, especially acidic mucopolysaccharides, which are matrix components of the scalp that fill the gaps between fimbriae proteins, as well as structural glycoproteins, such as hyaluronic acid, dermatan sulfate, chondroitin sulfate, and heparan. By migrating through a matrix component layer such as sulfuric acid, reaching the hair matrix cells, and being taken into the hair matrix cells, the expected hair growth, hair nourishment, and even hair growth effects are expressed.
然るに若し、該基質成分である酸性ムコ多糖類の上記成
分の存在量及びその構成比に何らかの支障を来した場合
、当然、毛母細胞賦活成分や栄養素の基質成分層での泳
動にも影響し、育毛、養毛、発毛等の効果が充分に発現
しない。However, if the abundance and composition ratio of the above-mentioned components of the acidic mucopolysaccharide, which is the matrix component, are disturbed in some way, it will naturally affect the migration of hair matrix activation components and nutrients in the matrix component layer. However, effects such as hair growth, hair growth, and hair growth are not fully expressed.
特に、男性の壮年性脱毛症の頭皮は、一般に表皮、真皮
ともに非薄化していることが知られており、また、円形
脱毛症の患部皮膚は発症時には弛緩傾向が見られるもの
の、治癒するに伴い段々と患部皮膚に弾力性が復元し、
発毛が認められるようになる。In particular, it is known that both the epidermis and dermis of the scalp of men with alopecia in their prime are generally non-thinning, and although the affected skin of alopecia areata tends to be flaccid at the time of onset, it takes a long time to heal. As a result, elasticity is gradually restored to the affected skin,
Hair growth becomes visible.
かかる頭皮真皮内の末梢毛細血管と毛母細胞と間に介在
する基質成分を正常化し、毛母細胞賦活成分や栄養素が
毛母細胞内に円滑に取り込まれるような成分を配合して
なる養毛化粧料の提案は未だ皆無である。A hair nourishing product that normalizes the matrix components interposed between the peripheral capillaries and hair matrix cells in the scalp dermis, and contains ingredients that allow hair matrix cell activation components and nutrients to be smoothly incorporated into the hair matrix cells. There are still no proposals for cosmetics.
（発明の開示）
そこで、本発明者は、頭皮の基質成分の正常化に資する
酸性ムコ多Ｗ類について、鋭意研究を重ねた結果、通常
化粧料に配合される酸性ムコ多糖れず、本発明が目的と
せる育毛、養毛、発毛等の効果が得られなかったが、後
記特定の低分子の酸性ムコ多糖類及びその塩類の少なく
とも一種と、γ−アミノ酪酸及びその誘導体より選ばれ
た少なくとも一種とを併用配合してなる養毛化粧料は、
本発明が目的とする育毛（マウス毛成長促進効果、ヒト
頭髪毛成長促進効果）、養毛、脱毛予防、ふけ防止等の
効果に更に一層優れていることを見出し、本発明を完成
するに至った。(Disclosure of the Invention) Therefore, as a result of extensive research into acidic mucopolysaccharides that contribute to the normalization of the matrix components of the scalp, the present inventor found that the acidic mucopolysaccharides that are usually incorporated in cosmetics are not present, and that the present invention has been developed. Although the desired effects such as hair growth, hair nourishment, and hair growth were not obtained, at least one selected from the following specific low-molecular-weight acidic mucopolysaccharides and salts thereof, and at least one selected from γ-aminobutyric acid and its derivatives. Hair nourishing cosmetics that are formulated in combination with one type of
We have discovered that the effects of the present invention, such as hair growth (mouse hair growth promotion effect, human hair growth promotion effect), hair growth, hair loss prevention, dandruff prevention, etc., are even more excellent, and we have completed the present invention. Ta.
（発明の目的）
即ち、本発明の目的は、育毛、養毛、脱毛予防１ふけ防
止等の効果に優れた養毛化粧料を提供することにある。(Objective of the Invention) That is, an object of the present invention is to provide a hair-growth cosmetic that is excellent in effects such as hair growth, hair growth, hair loss prevention, and dandruff prevention.
少な（とも一種と、Ｔ−アミノ酪酸及びその誘導体より
選ばれた少な（とも一種とを配合したことを特徴とした
養毛化粧料である。This is a hair-nourishing cosmetic that is characterized by containing one type of hair growth agent and one type of hair growth selected from T-aminobutyric acid and its derivatives.
（構成の具体的な説明）
本発明に用いる酸性ムコ多糖類、即ちヒアルロン酸、デ
ルマタン硫酸、コンドロイチン硫酸、ヘパラン硫酸等は
公知の物質であって、軟骨、関節、眼球、皮膚その他の
結合組織に基質成分となって、蛋白質と結合して動物体
内に広く分布している。(Specific explanation of composition) Acidic mucopolysaccharides used in the present invention, namely hyaluronic acid, dermatan sulfate, chondroitin sulfate, heparan sulfate, etc., are known substances and are useful for cartilage, joints, eyes, skin and other connective tissues. It serves as a matrix component, binds to proteins, and is widely distributed within the animal body.
本発明に用いる低分子の酸性ムコ多糖類及びそ平均分子
量が１００万の市販されているヒアルロン酸５ｇを、１
００ｍ１の０．０２Ｎの塩酸水溶液に分散溶解し、ｐＨ
＝２〜３に調製して充分に撹拌しつつ温浴中で６５°Ｃ
に加温した。この加温処理時間を各々１０分から１２０
分に変えることにより、平均分子量が１万から１００万
のヒアルロン酸を得ることができる。5 g of the low-molecular acidic mucopolysaccharide used in the present invention and commercially available hyaluronic acid with an average molecular weight of 1 million,
Dispersed and dissolved in 0.00ml of 0.02N hydrochloric acid aqueous solution, pH
= 2 to 3 and heated to 65°C in a hot bath with sufficient stirring.
It was heated to The heating treatment time is 10 minutes to 120 minutes each.
Hyaluronic acid having an average molecular weight of 10,000 to 1,000,000 can be obtained by changing the molecular weight to 1,000,000 to 1,000,000.
次いて、Ｎ−苛性ソーダで中和した後、該溶液を室温ま
で冷却し、エタノール３倍容を加えて得られる沈澱物を
エタノールで洗浄した後、乾かして低分子ヒアルロン酸
ナトリウム塩の粉末を得た。また、この低分子ヒアルロ
ン酸ナトリウム塩を酸で処理して遊離のヒアルロン酸と
し、次にこれを他の塩基性物質で処理して、例えば、カ
リウム塩、トリエタノールアミノ塩、Ｌ−アルギニン塩
平均分子量が５万の市販されているコンドロイチン硫酸
ナトリウム５ｇを５０ｍ１の水に溶かし、アンバーライ
トＩＲ−１２０（Ｈ型）のレジンカラムに通して得られ
る流出液を充分に撹拌しつつ、温浴中で７５℃に加温し
た。この加温処理時間を各々１０分から１２０分に変え
ることにより、平均分子量が２５００〜２００００のコ
ンドロイチン硫酸を得ることができる。次いて、Ｎ−苛
性ソーダで中和する。該溶液を室温まで冷却後、エタノ
ール３倍容を加えて得られる沈澱物を遠心分離し、エタ
ノールで洗滌した後、乾燥してコンドロイチン硫酸ナト
リウム塩の粉末を得た。次いて、このコンドロンチン硫
酸ナトリウム塩を酸で処理して遊離のコンドロイチン硫
酸とし、次にこれを他の塩基性物質で処理して、例えば
１、カリウム塩、トリエタノールアミン塩、Ｌ−アルギ
ニ硫酸等についても、上記コンドロイチン硫酸の例と同
様の処理により、遊離状或いはそれぞれの塩類を調製し
た。Next, after neutralizing with N-caustic soda, the solution was cooled to room temperature, and 3 times the volume of ethanol was added. The resulting precipitate was washed with ethanol and dried to obtain a powder of low molecular weight sodium hyaluronate salt. Ta. In addition, this low-molecular-weight sodium hyaluronate salt is treated with an acid to obtain free hyaluronic acid, which is then treated with other basic substances, such as potassium salt, triethanolamino salt, and L-arginine salt. Dissolve 5 g of commercially available sodium chondroitin sulfate with a molecular weight of 50,000 in 50 ml of water, and pass through a resin column of Amberlite IR-120 (H type). The resulting effluent is thoroughly stirred and heated to 75 mL in a hot bath. Warmed to ℃. By changing the heating treatment time from 10 minutes to 120 minutes, chondroitin sulfate having an average molecular weight of 2,500 to 20,000 can be obtained. It is then neutralized with N-caustic soda. After cooling the solution to room temperature, 3 times the volume of ethanol was added, and the resulting precipitate was centrifuged, washed with ethanol, and dried to obtain chondroitin sulfate sodium salt powder. This chondroitin sulfate sodium salt is then treated with an acid to give free chondroitin sulfate, which is then treated with other basic substances such as 1, potassium salt, triethanolamine salt, L-arginisulfate, etc. Also, free forms or their respective salts were prepared by the same treatment as in the example of chondroitin sulfate.
尚、各処理時間により得られた酸性ムコ多糖類の平均分
子量の測定方法は、ソモギーーネルソン（Ｓｏｍｏｇｙ
ｉ−Ｎｅｌｓｏｎ）法を用いた。The method for measuring the average molecular weight of the acidic mucopolysaccharide obtained for each treatment time is based on Somogy-Nelson (Somogy-Nelson).
i-Nelson) method was used.
更に、本発明が目的としている育毛、養毛、脱毛予防、
ふけ防止等の効果をより一層発揮させるため、併用する
血行促進剤についてスクリーニングしたところ、γ−ア
ミノ醋酸及びその誘導体が最も本発明の目的として期待
せる効果を示した。Furthermore, hair growth, hair nourishment, hair loss prevention, which is the purpose of the present invention,
In order to further exhibit the effects of preventing dandruff, we screened blood circulation promoters to be used in combination, and found that γ-aminoacetic acid and its derivatives showed the most promising effects for the purposes of the present invention.
本発明に用いるＴ−アミノ酪酸は公知の物質であって、
植物界に広く遊離の形で存在し、動物では脳内に多く、
脳の代謝に重要な役割を果たし、脳血管障害の後遺症の
改善、筋萎縮症の改善に用いられている。また、該物質
の皮膚に対する作用としては皮膚末梢血管拡張作用によ
り皮膚機能を亢進し、皮膚の疲労やたるみを治癒せしめ
、老化やしわを防止する作用があると言われている。T-aminobutyric acid used in the present invention is a known substance,
It exists widely in the plant kingdom in free form, and in animals it is abundant in the brain.
It plays an important role in brain metabolism and is used to improve the aftereffects of cerebrovascular disorders and muscular atrophy. In addition, the substance is said to have the effect of enhancing skin function by dilating skin peripheral blood vessels, curing skin fatigue and sagging, and preventing aging and wrinkles.
また、γ−アミノ酪酸の誘導体として、Ｎ−メチル−Ｔ
−アミノ酪酸又はＮ−ジメチル−Ｔ−アミノ酪酸及びそ
れらのメチルエステル、エチルエステル、プロピルエス
テル、ブチルエステル等、またＮ−ジメチル−Ｔ−アミ
ノ酪酸の２−エチルヘキシルエステル、オクチルエステ
ル、オレイルエステル、ラウリルエステル、ヘキサデシ
ルエステル、ステアリルエステル等が知られいてるが、
これらＴ−アミノ酪酸及びその誘導体のいずれも−７＝
が本発明の養毛化粧料に適用することができる。In addition, as a derivative of γ-aminobutyric acid, N-methyl-T
-aminobutyric acid or N-dimethyl-T-aminobutyric acid and their methyl esters, ethyl esters, propyl esters, butyl esters, etc., and 2-ethylhexyl ester, octyl ester, oleyl ester, lauryl ester of N-dimethyl-T-aminobutyric acid Esters, hexadecyl esters, stearyl esters, etc. are known, but
Any of these T-aminobutyric acids and their derivatives -7= can be applied to the hair nourishing cosmetic composition of the present invention.
本発明者は、養毛化粧料中に配合せる上記構成コ多Ｉｉ
類及びその塩、（２）Ｔ−アミノ酪酸及びその誘導体の
それぞれの配合量の比率（重量比）（１）：（２） ＝
１ ： ０． ０１〜１：１である場合が好ましく、本
発明の目的とする優れた効果が認められた。The present inventor has discovered that the above-mentioned components Ii to be incorporated into hair-growth cosmetics
and its salts, (2) T-aminobutyric acid and its derivatives (weight ratio) (1):(2) =
1:0. The ratio is preferably 01 to 1:1, and the excellent effects aimed at by the present invention were observed.
即ち、この（２）の血行促進剤が毛包上皮に隣接する真
皮内の末梢毛細血管の血行を促進し、血液中に含まれて
いる毛母細胞賦活成分と毛母細胞の栄養素の真皮組織内
への滲出を活発にし、更に、（１）が毛包上皮を取り囲
む基質成分の構成比を改善することにより、毛母細胞の
毛母細胞賦活成分等の物質の取り込みを円滑に行うなわ
しめ、毛の生育を促進するとともに、（１）の優れた抱
水能力が頭皮に適度な水の付与と保留に貢献し、ふけ防
止をも発現せしめるという効果を奏し得たのである。That is, the blood circulation promoting agent (2) promotes blood circulation in peripheral capillaries in the dermis adjacent to the hair follicle epithelium, and increases the amount of hair matrix cell activating components and hair matrix nutrients contained in the blood in the dermal tissue. In addition, (1) improves the composition ratio of matrix components surrounding the hair follicle epithelium, thereby facilitating the uptake of substances such as hair matrix activation components into hair matrix cells. In addition to promoting hair growth, the excellent water-holding ability of (1) contributes to the application and retention of an appropriate amount of water to the scalp, and has the effect of preventing dandruff.
及びその塩とＴ−アミノ酪酸及びその誘導体の配合割合
は、総量を基準として、（１）は０．Ｏ１〜２．０ｗｔ
％あればよく、各々の配合量の下限未満では、本発明が
目的とする効果に充分でなく、一方、上限を越えても、
その増加分に見合った効果の向上は望めないものである
。The blending ratio of T-aminobutyric acid and its salts to T-aminobutyric acid and its derivatives is 0.0% (1) based on the total amount. O1~2.0wt
% is sufficient, and if the amount is less than the lower limit of each compounding amount, it will not be sufficient to achieve the desired effect of the present invention.On the other hand, even if the amount exceeds the upper limit,
It is not possible to expect an improvement in effectiveness commensurate with the increase.
本発明の養毛化粧料には、上記の他に各種油剤、色素、
香料、防腐剤、界面活性剤、顔料、抗酸化剤等を本発明
の目的を達成する範囲内で適宜配合することができる。In addition to the above, the hair nourishing cosmetic of the present invention includes various oils, pigments,
Flavors, preservatives, surfactants, pigments, antioxidants, and the like can be added as appropriate within the range that achieves the purpose of the present invention.
本発明の養毛化粧料は、オイリーヘアートニック、スカ
ルプトリートメント、養毛ヘアーローション、養毛ヘア
ークリーム等に適用される。The hair nourishing cosmetic composition of the present invention is applicable to oily hair tonics, scalp treatments, hair nourishing hair lotions, hair nourishing hair creams, and the like.
（実施例）
以下、実施例及び比較例に基づき本発明の詳細な説明す
る。(Examples) Hereinafter, the present invention will be described in detail based on Examples and Comparative Examples.
尚、マウス毛成長促進試験、ヒト頭髪毛成長促進試験及
び実用試験を下記に示す。The mouse hair growth promotion test, human hair growth promotion test, and practical test are shown below.
（１）マウス毛成長促進試験
ｄｄｙ系白色マウス（雄・６週令・平均体重３５ｇ）の
尾部よりの背部皮膚を電気バリカンで刈った後、脱毛ク
リームにより完全に除毛し、翌日より実施例及び比較例
の各試料を被験部皮膚に毎日朝夕２回、１匹当りＯ，１
ｍｌ塗布した。１試料に対して動物は１群１０匹を使用
した。(1) Mouse hair growth promotion test After cutting the dorsal skin from the tail of DDY white mice (male, 6 weeks old, average weight 35 g) with electric clippers, the hair was completely removed with hair removal cream, and the test was carried out from the next day. and each sample of the comparative example was applied to the skin of the test subject twice a day in the morning and evening, at a dose of O.1 per animal.
ml was applied. Ten animals per group were used for one sample.
育毛効果の判定は、下記に示す判定基準による肉眼判定
の評価点と、毛長、毛重量を対照群と比較することによ
り行った。The hair growth effect was determined by comparing the visual evaluation score, hair length, and hair weight with the control group according to the criteria shown below.
実験開始後１５日目に動物を層殺し判定基準により肉眼
判定し、その評価点を合計し、１匹当りの平均評価点を
求めた。更に、被験部位の皮膚を打ち抜き乾燥した後、
毛重量を測定し、その中の２０本の毛の長さについても
測定し、各々の平均値で示した。On the 15th day after the start of the experiment, the animals were visually evaluated according to the stratification criteria, and the evaluation scores were totaled to determine the average evaluation score per animal. Furthermore, after punching out the skin at the test site and drying it,
The weight of the hair was measured, and the lengths of 20 of the hairs were also measured, and the average value of each hair was shown.
育毛効果の評価の判定基準
評価点５ 周囲の非抜毛部との境が不明〃 ４ 毛
成長強度
〃 ３ 毛成長中度
〃 ２ 毛成長軽度
〃 １ 毛成長極く軽度
〃 ０ 毛成長認められず
（２）ヒト頭髪毛成長促進試験
男性型脱毛症患者である被試験者１０名の頭部の耳の上
５ｃｍの位置の頭部を左右２ケ所に於いて直径１ｃｍの
円形状に剃毛した被験部位に、実施例または比較例の試
料を毎日朝夕２回、約３ｍ１塗布し、無処理の右側と比
較した。効果の判定は、試験開始後２８日目に、左右の
被験部位の毛髪各々２０本ずつ剃毛し、左側（実施例ま
たは比較例を塗布）の毛２０本の長さの平均値（Ｂ）を
右側（無処理）の毛２０本の長さの平均値（Ａ）で除し
た値を求めて評価した。Judgment criteria for hair growth effect evaluation score 5 The border with the surrounding non-hair-pulled area is unclear 4 Hair growth intensity 3 Moderate hair growth 2 Mild hair growth 1 Very light hair growth 0 No hair growth observed (2) Human hair growth promotion test The heads of 10 test subjects who were androgenetic alopecia patients were shaved in a circular shape with a diameter of 1 cm at two locations on the left and right, 5 cm above the ears. Approximately 3 ml of the sample of Example or Comparative Example was applied to the test site twice a day in the morning and evening, and compared with the untreated right side. To judge the effectiveness, on the 28th day after the start of the test, 20 hairs each on the left and right test sites were shaved, and the average length of the 20 hairs on the left side (where Example or Comparative Example was applied) (B) was divided by the average length (A) of 20 hairs on the right side (untreated) for evaluation.
判定の結果は、被試験者１０名の各々の（Ｂ）／（Ａ）
平均値で示した。The results of the judgment are (B)/(A) for each of the 10 test subjects.
Shown as average value.
（３）実用試験
男性型脱毛症患者である被試験者２０名の頭部に毎日朝
夕２回、連続６ケ月間試料を塗布した後の効果で評価し
た。試験結果は、養毛効果、脱毛予防効果、ふけ防止効
果の各項目に対して、「生毛が剛毛化した或いは生毛が
増加した」、「脱毛が少なくなった」、「ふけが少な（
なった」と回答した人数で示した。(3) Practical test Samples were applied to the heads of 20 test subjects suffering from androgenetic alopecia twice a day in the morning and evening for 6 consecutive months, and then the effects were evaluated. The test results showed that "grown hair became bristle or increased,""hair loss decreased," and "less dandruff (
It is shown by the number of people who answered "It has become."
比較例１〜１５、実施例１〜１０
〔オイリーへアートニック〕
下記の原料組成において、第１表（その１）及び第１表
（その２）記載の如く、ヒアルロン酸（以下、ＨＡと略
記する。以下同様）、ヒアルロン酸ナトリウム（ＨＡ−
Ｎａ）、コンドロイチン硫酸（Ｃｈｓ）、ヘパラン硫酸
（Ｈｐｓ）、コンドロイチン硫酸カリウム（ｃｂｓ−Ｋ
）、コンドロイチン硫酸トリエタノールアミン（Ｃｈ
ｓ −Ｔ）、デルマタン硫酸（Ｄ ｓ ） 、デルマタ
ン硫酸Ｌ−アルギニン（Ｄ ５−Ａ）並びにＴ−アミノ
醋酸（ＧＡＢＡ） 、Ｎ−メチル−γ−アミノ酪酸（Ｍ
−ＧＡ） 、Ｎ−メチル−Ｔ−アミノ酪酸チルエステル
（Ｍ−ＧＡ−Ｅ） 、Ｎ−ジメチル−Ｔ−アミノ酪酸（
ＤＭ−ＧＡ） 、Ｎ−ジメチル−Ｔ−アミノ酪酸ステア
リルエステル（ＤＭ−ＧＡ−３）等を配合して、各々の
オイリーヘアートニックを調製し、前記の諸試験を実施
した。Comparative Examples 1 to 15, Examples 1 to 10 [Artonic to Oily] In the following raw material composition, as described in Table 1 (Part 1) and Table 1 (Part 2), hyaluronic acid (hereinafter abbreviated as HA) was used. ), sodium hyaluronate (HA-
Na), chondroitin sulfate (Chs), heparan sulfate (Hps), chondroitin sulfate potassium (cbs-K
), chondroitin sulfate triethanolamine (Ch
s-T), dermatan sulfate (Ds), dermatan sulfate L-arginine (D5-A), T-aminoacetic acid (GABA), N-methyl-γ-aminobutyric acid (M
-GA), N-methyl-T-aminobutyric acid methyl ester (M-GA-E), N-dimethyl-T-aminobutyric acid (
DM-GA), N-dimethyl-T-aminobutyric acid stearyl ester (DM-GA-3), and the like were mixed to prepare each oily hair tonic, and the various tests described above were conducted.
（１）組成
（２）調製法
（Ｂ）成分の内、Ｔ−アミノ酪酸、Ｎ−メチル−Ｔ−ア
ミノ酪酸及びそれらのメチルエステル、エチルエステル
、プロピルエステル、ブチルエステル等は水やアルコー
ルに易溶のため、（Ｃ）成分に（Ｄ）成分を混合溶解し
た溶液に、更に（Ｂ）成分を均一に混合溶解し、この溶
液に（Ａ）成分を撹拌しつつ均一に混合分散し、次いて
容器に充填する。(1) Composition (2) Preparation method Among the components (B), T-aminobutyric acid, N-methyl-T-aminobutyric acid, and their methyl esters, ethyl esters, propyl esters, butyl esters, etc. are easily absorbed by water and alcohol. To dissolve, component (B) is uniformly mixed and dissolved in a solution of component (C) and component (D), and component (A) is uniformly mixed and dispersed in this solution while stirring. and fill it into containers.
また、（Ｂ）成分の内、Ｎ−メチル−Ｔ−アミノ酪酸ま
たはＮ−ジメチル−Ｔ−アミノ酪酸の２−エチルヘキシ
ルエステル、オクチルエステル、ステアリルエステル等
の油溶性物質については、予め（Ａ）成分中に混合溶解
せしめ、上記の方法と同様にして、オイリーヘアートニ
ックを調製する。In addition, among component (B), oil-soluble substances such as 2-ethylhexyl ester, octyl ester, and stearyl ester of N-methyl-T-aminobutyric acid or N-dimethyl-T-aminobutyric acid should be prepared in advance as component (A). Prepare an oily hair tonic in the same manner as above.
これらいずれのオイリーヘアートニックも使用時には、
内容物を均等に振盪分散してから使用する。When using any of these oily hair tonics,
Shake and distribute the contents evenly before use.
（３）特性
各オイリーヘアートニックの諸試験を実施した結果を第
１表（その１）及び第１表（その２）に記載した。(3) Characteristics The results of various tests conducted on each oily hair tonic are listed in Table 1 (Part 1) and Table 1 (Part 2).
比較例１〜１４のヒアルロン酸等の酸性ムコ多＊ｉ及び
その塩の一種と、ＧＡＢＡ及びその誘導体の一種とを併
用配合していないオイリーヘアートニックに比較して、
本発明の実施例１〜１０の毛髪化粧料は諸試験において
明らかに良好なる効果が認められた。Compared to the oily hair tonics of Comparative Examples 1 to 14 that do not contain acidic mucopoly*i such as hyaluronic acid and one of its salts, and GABA and one of its derivatives,
The hair cosmetics of Examples 1 to 10 of the present invention clearly showed good effects in various tests.
酸性ムコ多糖類及びその塩とＴ−アミノ酪酸及びその誘
導体とを、併用配合した養毛化粧料は優れた皮膚機能先
進作用を有することが明らかである。It is clear that a hair nourishing cosmetic containing a combination of acidic mucopolysaccharides and their salts and T-aminobutyric acid and its derivatives has an excellent effect on improving skin function.
比較例１６〜２２、実施例１１〜１５
〔スカルプトリートメント〕
実施例１と同様にして各々のスカルプトリートメントを
調製して諸試験を実施し、その結果を第一 １５−
（１）組成
−１６＝
（２）調製法
前記実施例のオイリーヘアートニックと同様に（Ｂ）成
分の内、水溶性の物質は予め（Ｃ）成分中に混合溶解せ
しめ、また、油溶性物質は（Ａ）成分中に混合せしめ、
更に、（Ｄ）成分の油相成分をそれぞれ８０°Ｃに加熱
溶融し、撹拌しながら水相成分を油相成分に加え、乳化
混合した後、更に撹拌しなから３０ ’Ｃまで冷却して
各々スカルプトリートメントを調製した。Comparative Examples 16 to 22, Examples 11 to 15 [Scalp Treatment] Each scalp treatment was prepared in the same manner as in Example 1 and various tests were conducted, and the results were summarized as follows. (2) Preparation method As with the oily hair tonic in the previous example, the water-soluble substances in component (B) are mixed and dissolved in component (C) in advance, and the oil-soluble substances are mixed and dissolved in component (A). mix,
Further, each of the oil phase components of component (D) was heated and melted at 80 °C, and the water phase component was added to the oil phase component while stirring, and after emulsifying and mixing, the mixture was further cooled to 30 °C without stirring. Scalp treatments were prepared for each.
（３）特性
第２表に示す如く、本発明の養毛化粧料である実施例１
１〜１５のスカルプトリートメントは、比較例１６〜２
２と比較して緒特性の全てに亘って優れていることが明
らかであり、配合特性に於（発明の効果）
以上記載の如く、本発明は、育毛、養毛、脱毛予防、ふ
け防止等の効果に優れた養毛化粧料を提供することは明
らかである。(3) Characteristics As shown in Table 2, Example 1 is a hair nourishing cosmetic of the present invention.
Scalp treatments 1 to 15 are Comparative Examples 16 to 2
It is clear that it is superior in all the properties compared to 2, and in terms of compounding properties (effects of the invention). It is clear that a hair nourishing cosmetic with excellent effects can be provided.
Claims (2)
も一種と、γ−アミノ酪酸及びその誘導体より選ばれた
少なくとも一種とを配合したことを特徴とした養毛化粧
料。(1) A hair nourishing cosmetic comprising at least one type of low molecular weight acidic mucopolysaccharide and its salt, and at least one type selected from γ-aminobutyric acid and its derivatives.
〜１０００００のヒアルロン酸、平均分子量が２０００
〜２００００のコンドロイチン硫酸、デルマタン硫酸及
びヘパラン硫酸である特許請求の範囲第（１）項に記載
の皮膚化粧料。(2) The low molecular weight acidic mucopolysaccharide has an average molecular weight of 1000
~100000 hyaluronic acid, average molecular weight 2000
20,000 chondroitin sulfate, dermatan sulfate, and heparan sulfate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29816186A JPS63150210A (en) | 1986-12-15 | 1986-12-15 | Hair-tonic cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29816186A JPS63150210A (en) | 1986-12-15 | 1986-12-15 | Hair-tonic cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63150210A true JPS63150210A (en) | 1988-06-22 |
Family
ID=17855986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP29816186A Withdrawn JPS63150210A (en) | 1986-12-15 | 1986-12-15 | Hair-tonic cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63150210A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6413008A (en) * | 1987-06-12 | 1989-01-17 | Unilever Nv | Skin treatment composition |
| JPH05117131A (en) * | 1991-10-24 | 1993-05-14 | Unie Colloid Kk | Hair tonic and its production |
| JPH0733635A (en) * | 1993-07-21 | 1995-02-03 | Kao Corp | Skin external preparation |
| WO2006101030A1 (en) * | 2005-03-22 | 2006-09-28 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, method for producing same, and cosmetic preparation and food composition containing same |
| WO2006087392A3 (en) * | 2005-02-21 | 2006-11-30 | Relivia S R L | Substances, compositions and methods for treating alopecia |
| JP2007176956A (en) * | 2007-03-30 | 2007-07-12 | Seikagaku Kogyo Co Ltd | Trichogenous agent |
| US8367818B2 (en) | 2006-02-24 | 2013-02-05 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, and cosmetic preparation, pharmaceutical composition, and food composition each using same |
| US10543159B2 (en) | 2014-11-20 | 2020-01-28 | Ezaki Glico Co., Ltd. | Hair papilla cell activator |
-
1986
- 1986-12-15 JP JP29816186A patent/JPS63150210A/en not_active Withdrawn
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6413008A (en) * | 1987-06-12 | 1989-01-17 | Unilever Nv | Skin treatment composition |
| JPH078770B2 (en) * | 1987-06-12 | 1995-02-01 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Skin treatment composition |
| JPH05117131A (en) * | 1991-10-24 | 1993-05-14 | Unie Colloid Kk | Hair tonic and its production |
| JPH0733635A (en) * | 1993-07-21 | 1995-02-03 | Kao Corp | Skin external preparation |
| WO2006087392A3 (en) * | 2005-02-21 | 2006-11-30 | Relivia S R L | Substances, compositions and methods for treating alopecia |
| US20080051351A1 (en) * | 2005-02-21 | 2008-02-28 | Carlo Ghisalberti | Substances, Compositions, and Methods for Treating Alopecia |
| JP2006265287A (en) * | 2005-03-22 | 2006-10-05 | Q P Corp | Low molecular weight hyaluronic acid and/or its salt, its manufacturing process and cosmetic and food composition containing it |
| WO2006101030A1 (en) * | 2005-03-22 | 2006-09-28 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, method for producing same, and cosmetic preparation and food composition containing same |
| JP4576583B2 (en) * | 2005-03-22 | 2010-11-10 | キユーピー株式会社 | Hyaluronic acid or a salt thereof, method for producing the same, and cosmetics and food compositions containing the same |
| US8933054B2 (en) | 2005-03-22 | 2015-01-13 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, method for producing same, and cosmetic preparation and food composition containing same |
| US8367818B2 (en) | 2006-02-24 | 2013-02-05 | Q.P. Corporation | Low molecular weight hyaluronic acid and/or salt thereof, and cosmetic preparation, pharmaceutical composition, and food composition each using same |
| JP2007176956A (en) * | 2007-03-30 | 2007-07-12 | Seikagaku Kogyo Co Ltd | Trichogenous agent |
| US10543159B2 (en) | 2014-11-20 | 2020-01-28 | Ezaki Glico Co., Ltd. | Hair papilla cell activator |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5037803A (en) | Product comprising a silicon organic compound combined with a cosmetically active substance | |
| US5407675A (en) | Method and composition for use on the scalp and eyebrow region of a subject | |
| JP3112436B2 (en) | In particular, the use of honey as a keratolytic agent to improve the brightness of the skin facial and treat wrinkles | |
| JP2007277245A (en) | USE OF C-GLYCOSIDE DERIVATIVE AS MEDICINE FOR PROTECTING AND/OR ACTIVATING gammadeltaT LYMPHOCYTE | |
| JPH07101831A (en) | Hair-tonic cosmetic | |
| CN107669546A (en) | A kind of eyelash growing liquid and preparation method thereof | |
| JPS63150210A (en) | Hair-tonic cosmetic | |
| JPH0465047B2 (en) | ||
| JP2559678B2 (en) | Hair nourishing cosmetics | |
| JPS60116618A (en) | Cosmetic | |
| JPS62175417A (en) | Hair tonic cosmetic | |
| JPS63132816A (en) | Hair-tonic cosmetic | |
| JPS63243016A (en) | Hair tonic cosmetic | |
| JP3045613B2 (en) | Hair restoration cosmetics | |
| JPH05170625A (en) | Hair tonic | |
| JP2793646B2 (en) | Hair restoration cosmetics | |
| JP3229503B2 (en) | Hair restoration cosmetics | |
| JP2931083B2 (en) | Skin cosmetics | |
| JPH04305517A (en) | Hair care cosmetics | |
| JPS62249907A (en) | Cosmetic | |
| RU2034532C1 (en) | Hair balsam | |
| JPH0853326A (en) | Cosmetic for hair | |
| JP2000026269A (en) | Cosmetic | |
| JP2553474B2 (en) | Skin cosmetics | |
| JPS63146806A (en) | Hair tonic cosmetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |